Advertisement
Screener

Collegium Pharmaceutical, Inc. (COLL) Graph

COLL Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $199.88M; Revenue including tax (m); Cost of revenue $89.59M; Research and development (m).
  • 2026-03-31: Revenue $193.52M; Revenue including tax (m); Cost of revenue $76.27M; Research and development (m).
  • 2025-12-31: Revenue $205.45M; Revenue including tax (m); Cost of revenue $77.07M; Research and development (m).
  • 2025-09-30: Revenue $209.36M; Revenue including tax (m); Cost of revenue $80.19M; Research and development (m).

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

COLL revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Azstarys$12.91MBelbuca$57.67MJornay Pm$46.06MNucynta ERAG$2.78MNucynta ER$15.72MNucynta IRAG$2.36MNucynta IR$14.36MSymproic$3.02MXtampza ER$45.01MRevenue$199.88MCost of revenue$89.59MGross profit$110.29MOperating expenses$106.59MOperating income$3.70MSelling, general& administrative$106.59MPre-tax income-$13.53MIncome tax$1.52MNet income-$15.05M

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

COLL revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Single ReportableSegment$199.88MRevenue$199.88MCost of revenue$89.59MGross profit$110.29MOperating expenses$106.59MOperating income$3.70MSelling, general& administrative$106.59MPre-tax income-$13.53MIncome tax$1.52MNet income-$15.05M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueRevenue including taxCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$199.88M(m)$89.59M(m)$106.59M$106.59M$1.52M-$15.05M
2026-03-31$193.52M(m)$76.27M(m)$86.35M$86.35M$4.24M$14.50M
2025-12-31$205.45M(m)$77.07M(m)$67.64M$67.62M$12.07M$16.96M
2025-09-30$209.36M(m)$80.19M(m)$67.10M$67.08M$11.93M$31.51M
2025-06-30$188.00M(m)$79.62M(m)$73.64M$73.28M$5.04M$11.98M
2025-03-31$177.76M(m)$80.43M(m)$76.42M$75.64M$705.00K$2.42M
2024-12-31$181.95M(m)$83.66M(m)$63.09M$60.18M$4.73M$12.54M
2024-09-30$159.30M(m)$62.51M(m)$61.95M$61.95M$6.25M$9.34M
2024-06-30$145.28M(m)$54.47M(m)$43.34M$43.34M$9.49M$19.61M
2024-03-31$144.92M(m)$53.47M(m)$41.98M$41.98M$8.91M$27.71M
2023-12-31$149.75M(m)$55.12M(m)$32.94M$32.94M$14.77M$31.94M
2023-09-30$136.71M(m)$56.40M(m)$35.30M$35.30M$8.15M$20.63M
2023-06-30$135.55M(m)$61.72M(m)$38.19M$38.19M$4.79M$13.01M
2023-03-31$144.77M(m)$67.36M(m)$52.77M$52.77M-$131.00K-$17.43M
2022-12-31$129.62M(m)$79.83M(m)$38.03M$38.03M-$592.00K-$7.20M
2022-09-30$127.01M(m)$68.17M(m)$38.37M$38.37M$975.00K$457.00K
2022-06-30$123.55M(m)$71.19M$0.00$41.25M$41.25M-$1.46M-$5.19M
2022-03-31$83.75M(m)$35.26M$0.00$54.53M$58.51M-$2.77M-$13.07M
2021-12-31$27.36M(m)$28.70M$1.61M$26.60M$32.79M-$13.84M-$25.03M
2021-09-30$78.84M(m)$32.73M$1.45M$30.51M$31.96M$991.00K$8.05M
2021-06-30$82.94M(m)$32.70M$3.46M$30.37M$33.83M-$61.85M$72.84M
2021-03-31$87.72M(m)$32.12M$2.93M$31.48M$34.41M-$188.00K$15.66M
2020-12-31$76.27M(m)$31.98M$2.47M$26.82M$29.30M$304.00K$6.96M
2020-09-30$79.18M(m)$30.98M$2.14M$26.43M$28.57M$280.00K$11.29M
2020-06-30$78.06M(m)$29.69M$2.49M$29.32M$31.82M$246.00K$8.06M
2020-03-31$76.51M(m)$37.52M$2.67M$31.26M$33.93M$246.00K$450.00K
2019-12-31$74.20M(m)$49.09M$2.40M$25.09M$27.49M(m)-$2.20M
2019-09-30$72.94M$72.94M$46.75M$2.49M$30.07M$32.56M$0.00-$6.11M
2019-06-30$75.04M$75.04M$48.65M$2.46M$28.93M$31.39M(m)-$4.71M
2019-03-31$74.52M$74.52M$49.16M$2.99M$32.35M$35.34M(m)-$9.70M
2018-12-31$73.43M(m)$29.73M$2.25M$30.45M(m)(m)$9.09M
2018-09-30$70.18M$70.18M$46.01M$1.91M$33.45M(m)(m)-$16.50M
2018-06-30$73.06M$73.06M$46.84M$2.24M$31.28M(m)(m)-$13.06M
2018-03-31$63.75M$63.75M$43.11M$2.27M$31.58M(m)(m)-$18.65M
2017-12-31$10.79M(m)$1.09M$2.19M$25.09M(m)(m)-$17.40M
2017-09-30$11.95M$11.95M$553.00K$2.07M$22.76M(m)(m)-$13.26M
2017-06-30$3.56M$3.56M$577.00K$2.18M$22.06M(m)(m)-$21.12M
2017-03-31$2.17M$2.17M$371.00K$2.13M$22.85M(m)(m)-$23.08M
2016-12-31(m)(m)(m)$3.33M$25.37M$28.88M(m)-$27.56M
2016-09-30(m)(m)(m)$3.25M$23.57M$26.85M(m)-$26.44M
2016-06-30(m)(m)(m)$4.30M$20.17M$24.47M(m)-$24.52M
2016-03-31(m)(m)(m)$4.06M$11.53M$15.59M(m)-$15.65M
2015-12-31(m)(m)(m)$1.53M(m)$9.44M(m)-$9.53M
2015-09-30(m)(m)(m)$3.36M$5.91M$9.27M(m)-$9.36M
2015-06-30(m)(m)(m)$1.64M(m)$4.58M(m)-$4.67M
2015-03-31(m)(m)(m)$1.45M(m)$3.63M(m)-$3.69M
2014-12-31(m)(m)(m)$2.31M(m)$3.33M(m)-$3.47M
2014-09-30(m)(m)(m)$5.82M(m)$6.50M(m)-$6.56M
2014-06-30(m)(m)(m)$3.56M(m)$4.09M(m)-$4.12M
2014-03-31(m)(m)(m)$3.27M(m)$3.75M(m)-$3.77M

Revenue and expense 6 month

Period endRevenueRevenue including taxCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$393.40M(m)$165.86M(m)$192.94M$192.94M$5.76M-$555.00K
2025-06-30$365.76M(m)$160.05M(m)$150.06M$148.92M$5.75M$14.40M
2024-06-30$290.20M(m)$107.94M(m)$85.32M$85.32M$18.40M$47.32M
2023-06-30$280.31M(m)$129.09M(m)$90.97M$90.97M$4.66M-$4.42M
2022-06-30$207.30M(m)$106.44M$3.98M$95.78M$99.77M-$4.23M-$18.26M
2021-06-30$170.66M(m)$64.83M$6.39M$61.84M$68.24M-$62.04M$88.50M
2020-06-30$154.57M(m)$67.22M$5.16M$60.58M$65.74M$246.00K$8.51M
2019-06-30$149.56M$149.56M$97.82M$5.45M$61.29M$66.74M(m)-$14.41M
2018-06-30$136.81M$136.81M$89.94M$4.50M$62.86M(m)(m)-$31.71M
2017-06-30$5.73M$5.73M$948.00K$4.31M$44.91M(m)(m)-$44.20M
2016-06-30(m)(m)(m)$8.36M$31.70M$40.06M(m)-$40.17M
2015-06-30(m)(m)(m)$3.09M(m)$8.21M(m)-$8.37M
2014-06-30(m)(m)(m)$6.83M(m)$7.83M(m)-$7.89M

Revenue and expense 9 month

Period endRevenueRevenue including taxCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-09-30$575.12M(m)$240.24M(m)$217.16M$216.00M$17.68M$45.91M
2024-09-30$449.50M(m)$170.44M(m)$147.27M$147.27M$24.64M$56.65M
2023-09-30$417.02M(m)$185.48M(m)$126.27M$126.27M$12.81M$16.21M
2022-12-31(m)(m)(m)$0.00(m)(m)(m)(m)
2022-09-30$334.31M(m)$174.61M$3.98M$134.15M$138.14M-$3.25M-$17.80M
2021-09-30$249.51M(m)$97.56M$7.84M$92.36M$100.20M-$61.05M$96.55M
2020-09-30$233.75M(m)$98.20M$7.30M$87.01M$94.31M$526.00K$19.79M
2019-09-30$222.50M$222.50M$144.57M$7.94M$91.36M$99.30M$0.00-$20.52M
2018-09-30$206.99M$206.99M$135.95M$6.41M$96.31M(m)(m)-$48.21M
2017-09-30$17.68M$17.68M$1.50M$6.38M$67.67M(m)(m)-$57.46M
2016-09-30(m)(m)(m)$11.62M$55.27M$66.91M(m)-$66.62M
2015-09-30(m)(m)(m)$6.44M$11.03M$17.47M(m)-$17.73M
2014-09-30(m)(m)(m)$12.65M(m)$14.34M(m)-$14.45M

Revenue and expense 12 month

Period endRevenueRevenue including taxCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-12-31$780.57M(m)$317.31M(m)$284.80M$283.62M$29.75M$63.00M
2024-12-31$631.45M(m)$254.10M$0.00$210.36M$207.45M$29.38M$69.00M
2023-12-31$566.77M(m)$240.60M$0.00$159.21M$159.21M$27.58M$48.00M
2022-12-31$463.93M(m)$254.44M$3.98M$172.19M$176.17M-$3.85M-$25.00M
2021-12-31$276.87M(m)$126.25M$9.45M$118.96M$132.99M-$74.89M$72.00M
2020-12-31$310.02M(m)$130.18M$9.77M$113.83M$123.60M$830.00K$26.75M
2019-12-31$296.70M(m)$193.66M$10.34M$116.45M$126.79M$0.00-$22.72M
2018-12-31$280.41M$280.41M$165.68M$8.66M$126.76M$135.42M(m)-$39.13M
2017-12-31$28.48M$28.48M$2.60M$8.57M$92.76M(m)(m)-$74.86M
2016-12-31$1.71M$1.71M$213.00K$14.95M$80.63M$95.79M(m)-$94.18M
2015-12-31(m)(m)(m)$7.97M$18.93M$26.91M(m)-$27.25M
2014-12-31(m)(m)(m)$14.96M$2.71M$17.66M(m)-$17.92M
2013-12-31(m)(m)(m)$14.16M(m)$16.04M(m)-$16.20M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Faeth Therapeutics, Inc. (FTH)United States$0.750B
Design Therapeutics, Inc. (DSGN)United States$0.766B-12.78
Verastem, Inc. (VSTM)United States$0.706B-1.71
Nuvectis Pharma, Inc. (NVCT)United States$0.705B-17.53
IRONWOOD PHARMACEUTICALS INC (IRWD)United States$0.694B5.37
Wave Life Sciences, Inc. (WVE)$0.780B-5.56
Olema Pharmaceuticals, Inc. (OLMA)United States$0.790B-5.35
Climb Bio, Inc. (CLYM)United States$0.683B-13.03
Aclaris Therapeutics, Inc. (ACRS)United States$0.792B-9.78
GERON CORP (GERN)United States$0.803B-12.14